IP Library Granted Patent US 11,801,225
Granted Patent B2
US 11,801,225 · App. 16/970,218 · Granted Oct 31, 2023

Oral dosage forms comprising a hops extract

Inventors: John Ronald Ingram (Auckland, NZ); Edward George Walker (Auckland, NZ)
Assignee: THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED
A61K9/4875A61K9/0053A61K9/4816A61K31/122A61K36/185
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,801,225
App. No.
16/970,218
Granted
Oct 31, 2023
Kind
B2
Abstract

This invention provides novel oral dosage forms comprising a hops extract. The oral dosage forms are capable of activating bitter taste receptors expressed in the gastrointestinal tract. The applications include but are not limited to the use of the oral dosage forms for reducing energy intake and/or appetite in a subject.

Claims (21)

1. A delayed release oral dosage form comprising a hops extract, wherein the acid component of the hops extract is not isomerized, wherein the oral dosage form comprises a hydroxypropylmethyl cellulose (HPMC) capsule comprising:

(a) 125 mg of a supercritical CO 2 hops extract from the cultivar Pacific Gem;

(b) approximately 141 mg canola oil;

(c) approximately 1 mg rosemary oil and; and

(d) optionally a viscosity modifier.

2. The oral dosage form according to claim 1 , wherein the hops extract comprises 25-100% w/w alpha-acids.

3. The oral dosage form according to claim 1 , wherein the alpha acid component of the hops extract comprises 10-45% cohumulone.

4. The oral dosage form according to claim 1 , wherein the oral dosage form comprises a viscosity modifier.

5. The oral dosage form according claim 1 , wherein the contents of the oral dosage form has a viscosity between 250 cP and 8000 cP.

6. A method of

(a) reducing appetite

(b) increasing satiety hormones

(c) weight management

(d) appetite control

(e) decreasing food intake

(f) inducing satiety and/or

(g) treating obesity

comprising administering an oral dosage form according to claim 1 to the subject.

7. The method according to claim 6 , wherein the oral dosage form is administered to the subject at least one hour before meal time.

8. The method according to claim 6 , wherein the subject is following an intermittent fasting protocol.

9. The method according to claim 6 , wherein the oral dosage form is administered to the subject during a period of fasting.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jun 24, 2026
From: THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED; NEW ZEALAND INSTITUTE FOR BIOECONOMY SCIENCE LIMITED
To: NEW ZEALAND INSTITUTE FOR BIOECONOMY SCIENCE LIMITED
Reel/Frame 075069/0306 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2020
From: INGRAM, JOHN RONALD; WALKER, EDWARD GEORGE
To: THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED
Reel/Frame 053528/0236 →
Priority Claims (1)
AU 2018900489 · Feb 16, 2018 · national
Continuity (1)
Related Publication 20210077412A1 · Mar 18, 2021